Form 8-K - Current report:
SEC Accession No. 0001683168-22-005667
Filing Date
2022-08-15
Accepted
2022-08-15 09:09:30
Documents
14
Period of Report
2022-08-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 26491
2 PRESS RELEASE cns_ex9901.htm EX-99.1 23236
6 GRAPHIC image_001.jpg GRAPHIC 4744
  Complete submission text file 0001683168-22-005667.txt   236872

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20220815.xsd EX-101.SCH 2962
4 XBRL LABEL FILE cnsp-20220815_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20220815_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3718
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 221162715
SIC: 2834 Pharmaceutical Preparations